IDEX-04-LUE. Prof. Rossignol has received board membership fees from Novartis, Relypsa, and Steathpeptides. Dr. Chouihed reports honoraria from Novartis. Prof Girerd reports honoraria from Novartis, Boehringer and Servier.

No abstract

ObjectivesTo assess the prognostic value of hyponatraemia, hyperglycaemia and impaired estimated glomerular filtration rate (eGFR) in predicting in-hospital death in patients with acute heart failure (AHF) admitted for acute dyspnoea in the emergency department.DesignRetrospective observational study.SettingEmergency Department of the University Hospital of Nancy. Data were collected from August 2013 to October 2015.ParticipantsThe analysis included 405 patients with AHF admitted for acute dyspnoea in an emergency department.ResultsThe population was elderly (mean age 82 years), 20.1% had hyponatraemia, 45.1% had hyperglycaemia and 48.6% had eGFR <50 mL/min/1.73 m2. Sixty-one patients (15.1%) died in hospital, mostly due to cardiac aetiology (58.3%). In multivariable analysis adjusted for key potential confounders, adjusted hyponatraemia (OR=2.40, (1.16 to 4.98), p=0.02), hyperglycaemia (OR=2.00, 1.06 to 3.76, p=0.03) and eGFR <50 mL/min/1.73 m2 (OR=1.97 (1.00 to 3.80), p=0.04*) were all identified as significant independent predictors of in-hospital death.ConclusionsResults of basic routine laboratory tests (hyponatraemia, hyperglycaemia and impaired eGFR) performed on admission in the emergency department are independently associated with in-hospital death. These inexpensive tests, performed as early as patient admission in the emergency department, could allow the early identification of patients admitted for AHF who are at high risk of in-hospital death.Trial registration numberNCT02800122.